Terms: = Pancreatic cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Clinical Outcome
6 results:
1. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract] [Full Text] [Related]
2. Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.
Tracht J; Zhang K; Peker D
J Histochem Cytochem; 2017 Jul; 65(7):399-405. PubMed ID: 28651471
[TBL] [Abstract] [Full Text] [Related]
3. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.
Lee HS; Park SB; Kim SA; Kwon SK; Cha H; Lee DY; Ro S; Cho JM; Song SY
Sci Rep; 2017 Jan; 7():41615. PubMed ID: 28134290
[TBL] [Abstract] [Full Text] [Related]
4. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.
Manuyakorn A; Paulus R; Farrell J; Dawson NA; Tze S; Cheung-Lau G; Hines OJ; Reber H; Seligson DB; Horvath S; Kurdistani SK; Guha C; Dawson DW
J Clin Oncol; 2010 Mar; 28(8):1358-65. PubMed ID: 20142597
[TBL] [Abstract] [Full Text] [Related]
5. Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1.
Bauer L; Venz S; Junker H; Brandt R; Radons J
Int J Oncol; 2009 Jul; 35(1):97-107. PubMed ID: 19513556
[TBL] [Abstract] [Full Text] [Related]
6. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
Wei Y; Xia W; Zhang Z; Liu J; Wang H; Adsay NV; Albarracin C; Yu D; Abbruzzese JL; Mills GB; Bast RC; Hortobagyi GN; Hung MC
Mol Carcinog; 2008 Sep; 47(9):701-6. PubMed ID: 18176935
[TBL] [Abstract] [Full Text] [Related]
